Not Applicable Not Applicable
Conditions
Interventions
For the initial pilot tests, 12 subjects will be selected to form a homogenous investigation group. A crossover design will be employed. Two intervention doses will be tested (150 mg and 300 mg Fruitf
Sponsors
Provexis (UK)
Inven2 (Norway)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Male subjects 2. No history of cardiovascular disorders but with some elevated risk factors 3. Over 35 years of age 4. Resting blood pressure above 135/90 5. Normal blood level ACE activity 6. Normal platelet aggregation response against ADP 7. Should not take any blood pressure medications and platelet-modulating drugs for at least 2 weeks
Exclusion criteria
Exclusion criteria: Does not fulfill inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ambulatory blood pressure monitoring over a 24-hour period will be used as the main outcome measure. Protocol to be confirmed. Static blood pressure measurements may also be carried out at convenient intervals. The primary end point is change in mean systolic blood pressure (mmHg) between baseline and each follow up point. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in mean diastolic blood pressure between baseline and each follow up point 2. Plasma ACE assessed at to and at t3 hours after consumption of supplements 3. Platelet response assessed at to and at t3 hours after consumption of supplements | — |
Countries
Norway
Contacts
Public ContactAsim Duttaroy
Outcome results
None listed